Abstracts tagged "Vasculitis"

Abstract Number: 0728 • ACR Convergence 2025
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
Susana Romero-Yuste¹, Marta Domínguez-Álvaro², Antonio Fernández-Nebro³, Miquel Blasco⁴, Beatriz Ventosa⁵, Javier Narváez⁶, Gema Fernández⁷, Iñigo Rúa-Figueroa⁸, Desirée Luis-Rodríguez⁹ and Manuel Macía¹⁰, ¹University Hospital Complex of Pontevedra, Pontevedra, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ⁴Hospital clinic Barcelona, Barcelona Spain, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital la Paz, Madrid, Madrid, Spain, ⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁹Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain, ¹⁰Hospital Universitario Nuestra Señora de Candelaria,, Tenerife, Spain
Background/Purpose: ANCA-associated vasculitides (AAV)—granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)are rare but severe systemic vasculitides with significant morbidity and…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
Abstract Number: 1623 • ACR Convergence 2025
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
Katarina Kmetova¹, Gavin Poppei², Kavya Sugur³, Julia Ford⁴, Wenying Liang⁴, Emily Chong⁴, Srilakshmi Yalavarthi⁴, NaveenKumar Somanathapura⁴, Nataliya Milman⁵, Peter Merkel⁶, Ora Singer⁷ and Yu (Ray) Zuo⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²University of Michigan, Ann arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵the Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 2700 • ACR Convergence 2025
Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad², Tom Hill³, Benjamin Turturice¹, Urvashi Kaundal¹, Paul Schaughency³, Bhavisha Patel⁴, Emma Groarke⁵, Neal Young⁵, Stefania Dell'orso¹ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Stockholm, Sweden, ³NIAID, NIH, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁵National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe adult-onset inflammatory disease caused by somatic mutations of the ubiquitin-like modifier activating enzyme…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 0759 • ACR Convergence 2025
Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Sehreen Mumtaz¹, Lerone Clark², Archit Srivastava², Hannah Langenfeld³, Andrew C. Hanson³, Cynthia Crowson⁴, Andy Abril², Nouran Eshak⁵, Megan Sullivan⁶, Matthew Koster³ and Kenneth Warrington³, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Stewartvillle, MN, ⁵Mayo Clinic, Arizona, Scottsdale, AZ, ⁶Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
Abstract Number: 1147 • ACR Convergence 2025
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Akhila Arya Perumangote Vasudevan¹, Vishnu Mulavini², Rasiya Hashim³, Madhumitha Rondla⁴ and Dileep C Unnikrishnan⁵, ¹Yale University/Bridgeport Hospital, Stratford, CT, ²Calicut Medical College, Stratford, ³Franciscan Health Olympia & Chicago Heights, [email protected], IL, ⁴Texas tech university health sciences center, El paso, El Paso, TX, ⁵Bridgeport Hospital, Stratford, CT
Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
Abstract Number: 1624 • ACR Convergence 2025
Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells
Luciana Yamamoto de Almeida¹, Kaitlin Quinn², James Simone², Lily Dai², Benjamin Turturice², Urvashi Kaundal², Chloe Palmer², Karyssa Stonick³, davide Randazzo⁴, Carmelo Carmona-Rivera⁵ and Peter Grayson⁶, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Takayasu's arteritis (TAK) is a rare, systemic, chronic large vessel vasculitis of unknown etiology primarily affecting the aorta and its branches. Arterial damage, with…
Abstract Number: 2510 • ACR Convergence 2025
Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.
Clara Rouane¹, Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Stan Faguer¹, Antoine Huart¹, David Ribes¹, Dominique Chauveau¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chaves¹, Emmanuelle Mouchon¹, Guillaume De Bonnecaze¹, Margaux Lafaurie¹, Guillaume Moulis¹ and Grégory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²CHU Toulouse, Toulouse University, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: ANCA specificity has shown an association with patients’ genetic profile, cytokine profile, certain clinical presentations, serologic response to treatment, and risk of recurrence.Severe infections…
Abstract Number: 2701 • ACR Convergence 2025
Ophthalmic Manifestations of Relapsing Polychondritis
Akash Gupta¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Nirali Bhatt⁴, Carol McAlear², Marcela ferrada⁵, Peter Grayson⁶, Peter Merkel² and Shubhasree Banerjee², ¹Hospital of University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, ⁵University of Maryland, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: The prevalence of ocular involvement (OI) in patients with relapsing polychondritis (RP) has not been well defined. This study aimed to describe ocular manifestations,…
Abstract Number: 0732 • ACR Convergence 2025
Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
marc Corbera-bellalta¹, Roser Alba-Rovira¹, Nina Visocnik¹, Farah Kamberovic¹, Ferran Araujo-Ayala¹, Georgina Espigol-Frigolé¹, Patricia Perez-Galán¹, Ken Bondensgaard², John Paolini³ and Maria Cid⁴, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Kiniksa Pharmaceuticals, Lexington, ³Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁴Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Background: Giant-cell arteritis(GCA) is a chronic inflammatory disease targeting large and medium-sized arteries. Inflammation-induced vascular remodeling leads to vascular occlusion, with ischemic complications. Myofibroblasts…
Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Sema Kaymaz-Tahra¹, Cansu Arslantürk Güneysu², Sinem Nihal Esatoglu³, Güllü Sandal Uzun⁴, Burak Ince⁵, Mete Kara⁶ and Gulen Hatemi³, ¹Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ²Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, ⁶Izmir City Hospital, Division of Rheumatology, Izmir
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…
Abstract Number: 1592 • ACR Convergence 2025
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Adrien Cottu¹, Irene Mattioli², Xavier Puéchal³, Loic Guillevin⁴, Mathieu Groh⁵, Camille Taillé⁶, Maxime Samson⁷, Pascal Cathébras⁸, Halil Yildiz⁹, Grégory Pugnet¹⁰, Stéphane Jouneau¹¹, Marie-Charlotte Besse¹², François Lifermann¹³, Jean-Philippe Martellosio¹⁴, Laurent Guilleminault¹⁵, Colas Tcherakian¹⁶, Yann Nguyen¹⁷, Claire Demoreuil¹⁸, Philippe Guilpain¹⁹, Giacomo Emmi²⁰ and Benjamin Terrier²¹, ¹Internal medicine departement, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Hôpital Foch, Suresnes, France, ⁶Bichat hospital, APHP, Paris, France, ⁷CHU Dijon Bourgogne, Dijon, France, ⁸Internal medicine department, CHU St-Etienne, Saint-Etienne, France, ⁹Internal medicine department, Saint-Luc, Saint-Luc, France, ¹⁰CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹¹Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ¹²Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ¹³Internal Medicine, CH de Dax, Dax, France, ¹⁴Internal medicine department, CHU Poitiers, Poitiers, France, ¹⁵CHU Toulouse, Toulouse University, Toulouse, France, ¹⁶Pneumology department, Foch, Suresnes, France, ¹⁷Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁸Internal medicine department, Brest CHU, Brest, France, ¹⁹Internal medicine department, CHU Montpellier, Montpellier, France, ²⁰Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ²¹Cochin Hospital, Paris, France
Background/Purpose: Glucocorticoid (GC)-dependent asthma and ENT exacerbations may persist in more than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab and benralizumab, monoclonal…

1
2
3
…
41
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].